Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma
Study Information
Alliance Study ID: CALGB-30601
NCT Study ID (ClinicalTrials.gov): NCT00509041
Alliance Committee: Respiratory Cancer
Disease or Cancer Type: Lung Cancer & Mesothelioma
Alliance Study Chair: Arkadiusz Dudek, MD
Status: COMPLETED
Study Description
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with previously treated malignant mesothelioma.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information